This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Arrowhead Pharmaceuticals, Inc.. Active years: 2024-2026.
Company Filing History:
Years Active: 2024-2026
Title: The Innovative Contributions of Ji Young Suk
Introduction
Ji Young Suk is a notable inventor based in San Diego, California. He has made significant contributions to the field of biotechnology, particularly in the development of RNA interference (RNAi) agents. His work focuses on innovative methods to inhibit the expression of specific genes, which has important implications for treating various diseases.
Latest Patents
Ji Young Suk holds a patent for "RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use." This patent describes RNAi agents and compositions that include these agents, aimed at inhibiting the expression of the SOD1 gene. The SOD1 RNAi agents disclosed in the patent are designed to reduce SOD1 activity, which can provide therapeutic benefits for conditions such as amyotrophic lateral sclerosis (ALS).
Career Highlights
Ji Young Suk is currently associated with Arrowhead Pharmaceuticals, Inc., where he continues to advance his research in RNAi technology. His innovative approaches have the potential to transform treatment options for patients suffering from neurodegenerative diseases.
Collaborations
Throughout his career, Ji Young Suk has collaborated with esteemed colleagues, including Christine Esau and Tao Pei. These collaborations have fostered a productive research environment, leading to advancements in the field of RNAi therapeutics.
Conclusion
Ji Young Suk's contributions to biotechnology, particularly through his patent on SOD1 RNAi agents, highlight his role as an influential inventor in the medical field. His work not only showcases the potential of RNAi technology but also emphasizes the importance of innovation in developing treatments for serious health conditions.